Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 676 results for diabetes

  1. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

  2. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  3. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  4. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

  5. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

  6. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  7. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

  8. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

  9. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  10. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  11. What is the optimal ratio of non-nitrogen energy to nitrogen in parenteral nutrition for preterm and term babies?

    ill health in later life (for example, risk of cardiovascular disease, diabetes and obesity-related conditions). Because of these risks,...

  12. Pyelonephritis (acute): antimicrobial prescribing (NG111)

    This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  13. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

  14. Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section (IPG528)

    Evidence-based recommendations on insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. The catheter aims to help induction by causing dilation of the cervix when the cervix is unfavourable for induction. The double balloon squeezes the cervix and stimulates local prostaglandin release, which leads to cervical ripening.

  15. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.